Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin (APHOS-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02811055
Recruitment Status : Unknown
Verified August 2017 by University Hospital, Rouen.
Recruitment status was:  Recruiting
First Posted : June 23, 2016
Last Update Posted : August 22, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Rouen

Brief Summary:

Aldosterone regulation is mediated by hormonal control, and nervous control. Autonomic nervous system action could be mediated by neuropeptides in the adrenal gland. Therefore, in pathological conditions and especially in diabetes, low-renin hypertension with normal or high plasma aldosterone could be caused by sympathetic nervous system hypertonia.

Data from the literature and previous in vitro research conducted in the investigators' laboratory (INSERM U982, University of Rouen) suggest that adrenal corticosteroid secretion might be controlled by sympathetic nervous system. This neurocrine regulation of corticosteroid secretion involves locally released neuropeptides. Among them, substance P is able to stimulate aldosterone and cortisol production via NK1 receptors. A previous clinical trial conducted at the University Hospital of Rouen, APHOS (NCT00977223) studied the effects of a NK1 receptor antagonist, aprepitant, on adrenocortical secretions in healthy volunteers.

The aim of the present study is to investigate the effects of a NK1 receptor antagonist, aprepitant, on adrenocortical secretions in volunteers with diabetes associated with low-renin hypertension. Aprepitant is a drug already available for the treatment of nausea induced by chemotherapy.

In the present phase II trial, plasma aldosterone and cortisol levels will be measured under treatment with aprepitant versus placebo, in both basal conditions and after activation of the adrenocortical function by upright posture. All volunteers will be given the two substances (aprepitant and placebo) in a random order during two 14 day-periods separated by a 21 day-wash-out.

This study should allow to determine the role of substance P in the control of corticosteroid production in human with diabetes, associated with a low-renin hypertension.


Condition or disease Intervention/treatment Phase
Type 2 Diabetes Hypertension Biological: Blood sampling Procedure: Blood Pressure Measurement Device: electrocardiogram Procedure: orthostatic test Drug: Administration of Aprepitant Drug: Administration of placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin
Actual Study Start Date : July 13, 2017
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Administration of Aprepitant
Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
Biological: Blood sampling
Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days

Procedure: Blood Pressure Measurement
Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days

Device: electrocardiogram
Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days

Procedure: orthostatic test
Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days

Drug: Administration of Aprepitant
Administration of Aprepitant 80 mg once per day during 14 days

Placebo Comparator: Administration of placebo
Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
Biological: Blood sampling
Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days

Procedure: Blood Pressure Measurement
Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days

Device: electrocardiogram
Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days

Procedure: orthostatic test
Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days

Drug: Administration of placebo
Administration of placebo once per day during 14 days




Primary Outcome Measures :
  1. Difference from baseline in Plasma aldosterone concentration [ Time Frame: Baseline and Day 14 ]
    Plasma aldosterone concentration is analyzed


Secondary Outcome Measures :
  1. Difference from baseline in Plasma cortisol [ Time Frame: Baseline and Day 14 ]
    Plasma cortisol concentration is analyzed

  2. Difference from baseline in plasma renin [ Time Frame: Baseline and Day 14 ]
    plasma renin concentration is analyzed

  3. Difference from baseline in blood electrolytes measurement [ Time Frame: Baseline and Day 14 ]
    blood electrolytes concentration is analyzed

  4. Difference from baseline in HOMA index [ Time Frame: Baseline and Day 14 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or menopausal female subjects;
  • Age ranging 18-30 years old;
  • Submitted to a social security regimen;
  • Agreeing to the study & Informed consent form signed;
  • Body mass index ([weight (kg)/height (m)]²) < 27;
  • No treatment received 6 weeks before inclusion;
  • No anomaly after: complete clinical examination, pulse and blood pressure measurement, ECG;
  • No biological abnormality after the following biological testing:

Hematology: white & red blood cells & platelets count, haemoglobin, hematocrit, Blood biochemistry: sodium, potassium, chloride, bicarbonate, creatinine, urea, Urinary biochemistry (24 h collection): cortisol, aldosterone, Serologies: HIV, HBV, HCV,

  • No participation in a clinical trial 3 months ago before inclusion,
  • Subscription to national social security,
  • Signed informed consent.

Exclusion Criteria:

  • Female subject potentially pregnant,
  • Subject younger than 18 year-old and older than 70 year-old,
  • Subject without diabetes condition or with diabetes but normal blood pressure (below 130/80 mmHg),
  • Subject with glycated hemoglobin HbA1c < 6.5% or >11%,
  • Subject with leuconeutropenia (neutrophils below 1700/mm3),
  • Subject with severe medical or surgical history,
  • Patients treated with drugs metabolized by CYP3A4 and CYP2C9: corticosteroids, vitamin K , hormonal contraceptives, tolbutamide, benzodiazepines, derived from ergot, antiepileptics, hypericum, macrolides, azole antifungals.
  • Patients treated with drugs interfering with the renin-angiotensin- aldosterone system : beta-blockers, diuretics , anti -aldosterone drugs , direct renin inhibitors , insulin,
  • type 2 diabetes patients with a vegetative autonomic neuropathy,
  • Patients with adrenal mass was diagnosed at imaging,
  • hepatic or renal impairment (defined respectively by secondary clinical and biological manifestations altered hepatocyte functions or estimated glomerular filtration rate less than 60 mL / min / 1.73 m2);nephrotic syndrome (defined by hypoalbuminemia less than 30 g / L associated with proteinuria at 3 grams / 24 hours);edematous syndrome (defined by the presence of edema of the lower limbs),
  • Orthostatic hypotension (defined by a decrease in systolic blood pressure of 20 mmHg and at least the diastolic blood pressure of 10 mmHg or more),
  • arrhythmias or cardiac conduction,
  • heart failure (NYHA class II minimum),
  • epilepsy,
  • serious psychiatric condition,
  • Severe allergic history, hypersensitivity to aprepitant,
  • People with hereditary problems of fructose intolerance, glucose malabsorption, galactose, or sucrase-isomaltase,
  • People with lactose intolerance,
  • subject unwilling or cannot be followed regularly. Persons deprived of their liberty by a judicial or administrative decision, those hospitalized without consent and those admitted to a health or social establishment for purposes other than research, the adults subject to a measure of legal protection or unable to consent may not be included.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02811055


Contacts
Layout table for location contacts
Contact: Julien WILS, Pharm +3323288 ext 8265 julien.wils@chu-rouen.fr
Contact: Julien BLOT julien.blot@chu-rouen.fr

Locations
Layout table for location information
France
Rouen University Hospital Recruiting
Rouen, France
Principal Investigator: Gaétan PREVOST, MD         
Sponsors and Collaborators
University Hospital, Rouen
Investigators
Layout table for investigator information
Principal Investigator: Gaétan PREVOST, MD Rouen University Hospital
Layout table for additonal information
Responsible Party: University Hospital, Rouen
ClinicalTrials.gov Identifier: NCT02811055    
Other Study ID Numbers: 2013/142/HP
First Posted: June 23, 2016    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Aprepitant
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action